Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics Inc | RCV000516715 | SCV000614964 | uncertain significance | not provided | 2018-09-26 | criteria provided, single submitter | clinical testing | |
Invitae | RCV002527520 | SCV003243941 | uncertain significance | Spastic paraplegia | 2023-08-04 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SACS protein function. ClinVar contains an entry for this variant (Variation ID: 448209). This variant has not been reported in the literature in individuals affected with SACS-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 198 of the SACS protein (p.Tyr198Cys). |
Natera, |
RCV001834670 | SCV002086751 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2020-10-22 | no assertion criteria provided | clinical testing |